Skip to content
Medical Health Aged Care

Kolmar BNH Sharpens Global Competitiveness with Dual Functionality of HemoHIM

Kolmar BNH 2 mins read
SEOUL, South Korea--BUSINESS WIRE--

Kolmar BNH (KOSDAQ: 200130), a leading Original Development Manufacturing (ODM) company for health functional foods, strengthens its market position by acquiring certification for the additional functionality of HemoHIM, a renowned Korean health supplement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620376394/en/

HemoHIM G, manufactured by Kolmar BNH and distributed by Atomy, contains Angelica sinensis, Ligusticum chuanxiong, and Paeonia lactiflora. It was launched in Taiwan last month. (Photo: Kolmar BNH)

HemoHIM G, manufactured by Kolmar BNH and distributed by Atomy, contains Angelica sinensis, Ligusticum chuanxiong, and Paeonia lactiflora. It was launched in Taiwan last month. (Photo: Kolmar BNH)

The company secured approval from the Ministry of Food and Drug Safety for the fatigue-improving function of the HemoHIM extract complex of angelica gigas, etc., derived from angelica gigas and other components in 2023. This achievement was made six years after the launch of its HemoHIM Sustainable Technology Development Project. As a result, HemoHIM came to the market as a dual-functional health product designed to boost immune function and reduce fatigue.

HemoHIM, developed by Kolmar BNH in 2006, is the nation’s first individually-approved immune-boosting health supplement, formulated using indigenous natural ingredients like angelica gigas, cnidium officinale, and paeonia japonica. Distributed by Atomy, it's now a global success, exported to over 20 countries and generating over KRW 2 trillion in sales with exports exceeding $200 million. It has remained Korea's top-selling immune booster for over a decade.

Kolmar BNH validated the fatigue improvement function of HemoHIM through extensive clinical (human trials) and non-clinical trials (cell tests). In trials involving adults aged 30 to 59 experiencing fatigue, significant enhancements were observed in fatigue measures, including the Fatigue Severity Scale (FSS) and Multidimensional Fatigue Inventory (MFI), following consumption of the HemoHIM extract complex of angelica gigas, etc. These findings were published in Phytomedicine Plus, an international journal dedicated to natural medicine, with patents registered in Korea and Russia.

Continuing its commitment to innovation following the launch of HemoHIM, Kolmar BNH allocates over 2% of its annual sales to R&D. This investment aims to enhance product functionality and fortify competitive advantage.

HemoHIM G, targeting the global market, is one of the results of such dedication to R&D. Launched in Taiwan last month, HemoHIM G is a new product for export that has made meticulous adjustments to its raw materials and ingredient proportions to comply with international food regulations. Its key ingredients such as Angelica sinensis, Ligusticum chuanxiong, and Paeonia lactiflora went through rigorous sourcing procedures and stringent quality control. The taste and aroma profiles were tailored to suit the preferences of global consumers. Furthermore, its safety has been certified in the prestigious academic journal “Toxicological Research”, accredited at the SCIE level.

Kolmar BNH official said, "Through relentless research and development efforts, Kolmar BNH has enhanced the competitiveness of HemoHIM. We are dedicated to promoting K-health functional food globally through ongoing innovations in HemoHIM."


Contact details:

Kolmar BNH
Jang Woo Lee
jay.lee@kolmar.co.kr

Media

More from this category

  • Community, Medical Health Aged Care
  • 22/07/2024
  • 17:24
Odyssey Lifestyle Care Communities

Dancing and dining; seniors celebrate four fabulous years

Odyssey Lifestyle Care Communities recently celebrated a significant milestone in style, marking its fourth birthday with an evening full of fun, fantastic food and…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 22/07/2024
  • 12:56
Illumina

Research into psychedelic medicines to treat anxiety wins ANS Illumina Neurogenomics Award 2024

Genomic technologies to discover biological markers, within the blood, that could predict patient response to psychedelic medicines such as psilocybin. MELBOURNE, AUSTRALIA, 22 July 2024 - Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the winner of the annual Australasian Neuroscience Society (ANS) Illumina Neurogenomics Research Award as Dr Andrew Gibbons from the Department of Psychiatry, School of Clinical Sciences at Monash Health. “Psilocybin, a chemical produced by hallucinogenic mushrooms, is a psychedelic medicine that has shown to meaningfully reduce symptoms of generalized anxiety during psychotherapy for patients. However, not all patients respond.…

  • Contains:
  • Industrial Relations, Medical Health Aged Care
  • 22/07/2024
  • 11:12
Australian Nursing and Midwifery Federation (Victorian Branch)

Bolton Clarke nurses and carers to hold stop-work rally – Mon 22 July, 1pm-2pm

WHATANMF Bolton Clarke members two-hour stop work and community rally for fair pay and conditionsACTU Secretary Sally McManus and VTHC Secretary Luke Hilakari will address the rally WHENMonday, 22 July 2024, 1pm-3pm. (Speakers will start 1.05pm sharp) WHEREoutside Bolton Clarke’s Victorian headquarters, 347 Burwood Highway, Forest Hill Bolton Clarke nurses, personal care workers and midwives will stop work for two hours on Monday 22 July to rally for better pay and conditions. For the past 18 months, the Australian Nursing and Midwifery Federation (Victorian Branch) has been negotiating wages and conditions on behalf of about 1700 members working across Bolton…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.